Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 450,000 | 532.2% |
| Gross Profit | -2M | 25.9% |
| Cost of Revenue | 2.4M | 11.5% |
| Operating expense | 5.1M | 40.9% |
| Net Income | -2.4M | 41.7% |
| EBITDA | -2.1M | 6.8% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 7.4M | 18.6% |
| Total Liabilities | 9.9M | 24.4% |
| Shares Outstanding | 16M | 14.8% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | -5.3M | 99.4% |
| Cash from financing | 2.6M | 63.8% |
EPS
Financial Highlights for CERo Therapeutics in Q2 '24
CERo Therapeutics reported a revenue of 450,000, which is a 532.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -2M, marking a 25.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.4M, a -11.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 5.1M, showing a 40.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.4M, showing a -41.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -2.1M, showing a -6.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
CERo Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
